Drug Opioid Overdose

Nalmefene Hydrochloride

Payments companies reported to CMS as associated with Nalmefene Hydrochloride. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$84Kassociated payments (2023-2025)
498clinicians with associated payments
1company reporting

By year

2023 $11K
2024 $31K
2025 $43K

Payments reported as associated with Nalmefene Hydrochloride, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Emergency Medicine $26K
Pediatric Anesthesiology $11K
Pediatric Critical Care Medicine $6,198
Pediatric Emergency Medicine (Pediatrics) $6,016
Pain Medicine (Anesthesiology) $5,118
Anesthesiology $4,149

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Nalmefene Hydrochloride

These are the largest totals companies reported as associated with Nalmefene Hydrochloride. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Glen Apseloff Columbus, OH $15,955.09
Jeffrey Galinkin Aurora, CO Pediatric Anesthesiology $10,518.00
David Miramontes San Antonio, TX Emergency Medicine $8,061.99
Michael Gardiner San Diego, CA Pediatric Emergency Medicine (Pediatrics) $6,016.00
Rachael Rzasa-Lynn Aurora, CO Pain Medicine (Anesthesiology) $5,118.00
David Drover Stanford, CA Anesthesiology $4,130.00
John Berkenbosch Louisville, KY Pediatric Critical Care Medicine $3,825.00
Rahul Nene San Diego, CA Emergency Medicine $3,178.00
Justin Seltzer San Diego, CA Emergency Medicine $3,178.00
Christian Tomaszewski San Diego, CA Medical Toxicology (Emergency Medicine) $3,178.00

Prescribed Nalmefene Hydrochloride?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.